Singapore markets closed
  • Straits Times Index

    3,269.27
    -32.69 (-0.99%)
     
  • Nikkei

    28,546.98
    +727.65 (+2.62%)
     
  • Hang Seng

    20,175.62
    +93.19 (+0.46%)
     
  • FTSE 100

    7,493.46
    +27.55 (+0.37%)
     
  • BTC-USD

    23,861.57
    -846.28 (-3.43%)
     
  • CMC Crypto 200

    567.11
    -4.18 (-0.73%)
     
  • S&P 500

    4,232.19
    +24.92 (+0.59%)
     
  • Dow

    33,443.26
    +106.59 (+0.32%)
     
  • Nasdaq

    12,890.85
    +110.93 (+0.87%)
     
  • Gold

    1,808.20
    +1.00 (+0.06%)
     
  • Crude Oil

    91.32
    -3.02 (-3.20%)
     
  • 10-Yr Bond

    2.8530
    -0.0350 (-1.21%)
     
  • FTSE Bursa Malaysia

    1,506.19
    +0.63 (+0.04%)
     
  • Jakarta Composite Index

    7,129.28
    -31.11 (-0.43%)
     
  • PSE Index

    6,699.66
    +18.98 (+0.28%)
     

FENC – Fennec Pharmaceuticals Inc. Investors Who Have Lost More Than $25,000 Are Encouraged To Contact Kehoe Law Firm, P.C. – Securities Class Action Investigation

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
GlobeNewswire Inc.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

PHILADELPHIA, Nov. 30, 2021 (GLOBE NEWSWIRE) — Kehoe Law Firm, P.C. is investigating whether Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) violated federal securities laws or engaged in other unlawful business practices.

FENNEC INVESTORS WITH FINANCIAL LOSSES GREATER THAN $25,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE.

On November 29, 2021, Fennec reported that “. . . it expects the U.S. Food and Drug Administration will not accept the company’s New Drug Application for PEDMARK™.”

The Company also stated that “. . . it expects to receive a Complete Response Letter (CRL) after the PDUFA target action date of November 27, 2021 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for PEDMARKTM (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients ≥1 month to 18 years of age with localized, non-metastatic, solid tumors.”

Further, Fennec reported that “[t]he FDA has indicated that, following a recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, deficiencies have been identified.”

On this news, shares of Fennec declined $4.86 per share on November 29, 2021, thereby injuring investors. During intraday trading on November 30, 2021, Fennec shares were down more than 6%.

FENNEC INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE COMPANY’S SECURITIES AND LOST MORE THAN $25,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, JKEHOE@KEHOELAWFIRM.COM, OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, MYARNOFF@KEHOELAWFIRM.COM, INFO@KEHOELAWFIRM.COM, TO DISCUSS THE FENNEC SECURITIES CLASS ACTION INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.

This press release may constitute attorney advertising.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting